Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3200 participants.

Also called NCT04045665

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04045665
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Brazil, Canada, Germany, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04045665. Randomized; no masking; primary purpose treatment. Start 2019-12-13 (actual); primary completion 2026-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Acronym
PACES
Condition
Stroke
Condition
Bleeding
Intervention (Drug)
Antiplatelet-only strategy
Intervention (Drug)
Oral Anticoagulant plus background antiplatelet therapy
Lead sponsor
Icahn School of Medicine at Mount Sinai (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)
Collaborator
Vanderbilt University Medical Center (class: other)

Record details

Record id
cardio:ct-nct04045665
Content hash
e814aaa752531c4c8ede82f354f70656bf3fdb3275f3b1ffa4b9b666aeb3d304